Get the Stockscreener App
8.86
1.01%
-0.09
After Hours:
8.86
Pharming Group N V Adr Stock (PHAR) Forecast
The Pharming Group N V Adr (PHAR) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $4.7399, representing a -46.50% decrease from the current price of $8.86. The highest analyst price target is $5.6534, and the lowest is $3.8263.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month PHAR Price Target
Average 5.4706
(-38.25% Downside)
Is Pharming Group N V Adr (PHAR) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 48.50 | Neutral |
| STOCH(9,6) | 70.58 | Neutral |
| STOCHRSI(14) | 59.01 | Neutral |
| MACD(12,26) | -0.0718 | Buy |
| ADX(14) | 18.11 | Neutral |
| William %R | -41.29 | Neutral |
| CCI(14) | 44.75 | Neutral |
Buy: 1
Sell: 0
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
8.8896
Sell
|
8.8933
Sell
|
| MA20 |
8.8132
Buy
|
8.9387
Sell
|
| MA50 |
9.2507
Sell
|
8.9556
Sell
|
| MA100 |
8.7412
Buy
|
8.8291
Buy
|
| MA200 |
8.5036
Buy
|
9.1492
Sell
|
Buy: 4
Sell: 6
Neutral: 0
Summary: Sell
According to our latest analysis, PHAR could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on PHAR, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 48.5 indicates that PHAR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 70.58 indicates that PHAR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 59.01 indicates that PHAR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 18.11 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 44.75 indicates that PHAR is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term PHAR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Pharming Group N V Adr financial reports and earnings history, Pharming Group N V Adr (PHAR) stock could reach $4.0928 by 2030, $12.77 by 2040 and $11.12 by 2050. See the projected annual prices until 2050 of the Pharming Group N V Adr stock below:
- Pharming Group N V Adr (PHAR) is expected to reach an average price of $1.1361 in 2035, with a high prediction of $2.1061 and a low estimate of $0.1603. This indicates an $-87.18% rise from the last recorded price of $8.86.
- Pharming Group N V Adr (PHAR) stock is projected to chart a bullish course in 2040, with an average price target of $12.60, representing an $42.26% surge from its current level. The forecast ranges from a conservative $12.77 to a sky-high $12.77.
- Our analysts predict Pharming Group N V Adr (PHAR) to jump 14.37% by 2045, soaring from $11.10 to an average price of $10.13, potentially reaching $11.72. While $11.10 is the low estimate, the potential upside is significant.
- Pharming Group N V Adr (PHAR) stock is expected to climb by 2050, reaching an average of $10.66, a $20.32% jump from its current level. However, a wide range of estimates exists, with high and low targets of $11.12 and $11.26, respectively, highlighting the market's uncertainty.
Pharming Group N V Adr Stock (PHAR) Year by Year Forecast
Pharming Group N V Adr Stock (PHAR) Price Forecast for 2025
Pharming Group N V Adr Stock (PHAR) is expected to reach an average price of $4.292 in 2025, with a high prediction of $6.5951 and a low estimate of $1.9889. This indicates an -51.56% fall from the last recorded price of $8.86.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $4.6063 | $3.8263 | $5.6534 | -48.01% |
| April, 2025 | $3.6845 | $3.5845 | $5.714 | -58.41% |
| May, 2025 | $4.4251 | $3.2322 | $4.8691 | -50.06% |
| June, 2025 | $4.947 | $4.2827 | $5.2504 | -44.16% |
| July, 2025 | $4.3138 | $3.4733 | $6.0641 | -51.31% |
| August, 2025 | $3.9644 | $3.1767 | $5.3091 | -55.26% |
| September, 2025 | $5.0949 | $3.582 | $5.7073 | -42.50% |
| October, 2025 | $3.893 | $2.5531 | $5.2202 | -56.06% |
| November, 2025 | $3.8879 | $2.9508 | $4.5584 | -56.12% |
| December, 2025 | $3.7719 | $1.9889 | $4.6642 | -57.43% |
Pharming Group N V Adr Stock (PHAR) Price Forecast for 2026
The predicted value for Pharming Group N V Adr (PHAR) in 2026 is set at an average of $8.4099. Estimates vary from a peak of $14.05 to a trough of $2.7695, indicating an -5.08% surge from the present price of $8.86.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $3.5582 | $2.7695 | $4.0948 | -59.84% |
| February, 2026 | $8.093 | $3.55 | $8.9524 | -8.66% |
| March, 2026 | $7.1615 | $3.9965 | $8.7759 | -19.17% |
| April, 2026 | $5.5472 | $4.6841 | $8.0664 | -37.39% |
| May, 2026 | $7.5622 | $5.0493 | $8.7646 | -14.65% |
| June, 2026 | $9.3528 | $7.1049 | $9.3528 | +5.56% |
| July, 2026 | $8.291 | $6.4708 | $9.7377 | -6.42% |
| August, 2026 | $9.5415 | $7.5881 | $11.16 | +7.69% |
| September, 2026 | $8.4297 | $6.5045 | $10.95 | -4.86% |
| October, 2026 | $11.20 | $5.8826 | $14.05 | +26.42% |
| November, 2026 | $6.9708 | $6.4209 | $10.35 | -21.32% |
| December, 2026 | $8.889 | $6.5037 | $9.3137 | +0.33% |
Pharming Group N V Adr Stock (PHAR) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Pharming Group N V Adr (PHAR) is $9.5702, with a high forecast of $13.16 and a low forecast of $5.9762. This indicates an +8.02% increase from the last price of $8.86.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $8.3917 | $7.152 | $9.0896 | -5.29% |
| February, 2027 | $8.5701 | $7.3148 | $8.7801 | -3.27% |
| March, 2027 | $8.2383 | $7.4254 | $9.0983 | -7.02% |
| April, 2027 | $8.6889 | $8.176 | $9.336 | -1.93% |
| May, 2027 | $8.6944 | $6.4618 | $13.16 | -1.87% |
| June, 2027 | $8.5576 | $6.1847 | $8.8771 | -3.41% |
| July, 2027 | $8.0882 | $7.4229 | $9.0152 | -8.71% |
| August, 2027 | $7.9987 | $6.5511 | $8.9687 | -9.72% |
| September, 2027 | $9.3569 | $7.6363 | $9.7239 | +5.61% |
| October, 2027 | $8.3874 | $7.5824 | $9.8298 | -5.33% |
| November, 2027 | $8.1568 | $7.0404 | $8.8604 | -7.94% |
| December, 2027 | $6.7062 | $5.9762 | $8.4756 | -24.31% |
Pharming Group N V Adr Stock (PHAR) Price Forecast for 2028
In 2028, Pharming Group N V Adr (PHAR) is projected to reach an average price of $3.7729, with a high projection of $7.4238 and a low estimate of $0.122. This indicates an -57.42% fall from the last price of $8.86.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $5.705 | $4.83 | $7.4238 | -35.61% |
| February, 2028 | $4.8711 | $4.0711 | $6.0453 | -45.02% |
| March, 2028 | $3.9975 | $3.3122 | $5.2864 | -54.88% |
| April, 2028 | $3.5386 | $2.9287 | $4.528 | -60.06% |
| May, 2028 | $3.62 | $3.4597 | $4.335 | -59.14% |
| June, 2028 | $2.9961 | $2.7255 | $4.3002 | -66.18% |
| July, 2028 | $2.6322 | $1.8472 | $3.2913 | -70.29% |
| August, 2028 | $2.4035 | $1.7835 | $2.6224 | -72.87% |
| September, 2028 | $1.0797 | $1.0294 | $2.5241 | -87.81% |
| October, 2028 | $0.8058 | $0.8058 | $2.1404 | -90.91% |
| November, 2028 | $0.6221 | $0.2021 | $1.326 | -92.98% |
| December, 2028 | $0.2932 | $0.122 | $1.328 | -96.69% |
Pharming Group N V Adr Stock (PHAR) Price Forecast for 2029
The 2029 price forecast for Pharming Group N V Adr Stock (PHAR) is $2.4723 on average, with a high prediction of $4.9253 and a low estimate of $0.0193. This represents an -72.10% decrease from the previous price of $8.86.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.5603 | $0.1215 | $0.8585 | -93.68% |
| February, 2029 | $0.8307 | $0.0193 | $0.9407 | -90.62% |
| March, 2029 | $0.4143 | $0.126 | $0.9513 | -95.32% |
| April, 2029 | $0.7528 | $0.0476 | $1.7927 | -91.50% |
| May, 2029 | $0.5693 | $0.4763 | $1.2293 | -93.57% |
| June, 2029 | $0.2604 | $0.0404 | $1.5046 | -97.06% |
| July, 2029 | $0.1185 | $0.829 | $0.401 | -98.66% |
| August, 2029 | $0.9521 | $0.1379 | $0.6721 | -89.25% |
| September, 2029 | $0.739 | $0.3163 | $0.5684 | -91.66% |
| October, 2029 | $2.1654 | $0.4999 | $2.6554 | -75.56% |
| November, 2029 | $4.5665 | $2.5306 | $4.9253 | -48.46% |
| December, 2029 | $1.8776 | $1.4776 | $4.7717 | -78.81% |
Pharming Group N V Adr Stock (PHAR) Price Forecast for 2030
Pharming Group N V Adr Stock (PHAR) is expected to reach an average price of $5.5043 in 2030, with a high forecast of $10.29 and a low forecast of $0.7181. This signifies an -37.87% decrease from the last price of $8.86.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $1.8039 | $0.7181 | $4.0928 | -79.64% |
| February, 2030 | $3.935 | $2.0787 | $4.8292 | -55.59% |
| March, 2030 | $3.3601 | $2.9281 | $5.8482 | -62.08% |
| April, 2030 | $5.7373 | $2.6041 | $5.7973 | -35.25% |
| May, 2030 | $6.0736 | $4.6986 | $7.3125 | -31.45% |
| June, 2030 | $4.8347 | $2.6989 | $6.1689 | -45.43% |
| July, 2030 | $4.4211 | $2.1153 | $10.29 | -50.10% |
| August, 2030 | $3.8322 | $2.6918 | $5.2214 | -56.75% |
| September, 2030 | $4.6333 | $2.7975 | $5.6075 | -47.71% |
| October, 2030 | $4.3597 | $3.484 | $5.4291 | -50.79% |
| November, 2030 | $4.7708 | $3.8108 | $5.476 | -46.15% |
| December, 2030 | $5.1019 | $4.4413 | $5.7519 | -42.42% |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):